Mean Platelet Volume-To-Lymphocyte Ratio Predicts Poor Functional Outcomes Among Ischemic Stroke Patients Treated With Intravenous Thrombolysis

• Main Authors: Si-Yan Chen, Yuan-Shao Lin, Yi-Fan Cheng, Hong Wang, Xiao-Ting Niu, Wan-Li Zhang
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2019-12-01
• Series: Frontiers in Neurology
• Subjects: ischemic stroke; mean platelet volume; MPVLR; thrombolysis; outcomes
• Online Access: https://www.frontiersin.org/article/10.3389/fneur.2019.01274/full

Background and Purpose: According to previous studies, the mean platelet volume-to-lymphocyte ratio (MPVLR) represents a novel marker of a poor short-term prognosis in patients with a myocardial infarction who underwent primary percutaneous coronary intervention. We aimed to evaluate the association between MPVLR and clinical outcomes of patients with acute ischemic stroke who were treated with intravenous thrombolysis.Methods: Two hundred forty-one patients with ischemic stroke receiving intravenous thrombolysis were prospectively enrolled in this study. Blood samples for MPVLR were obtained at admission and at 18–24 h after treatment with intravenous thrombolysis. A poor functional outcome was defined as a modified Rankin scale score of 3–6 at 3 months after stroke.Results: At admission, the area under the curve of MPVLR to predict poor functional outcomes at 3 months was 0.613 [95% confidence interval (CI), 0.541–0.686; P = 0.003), and the best predictive MPVLR value was 5.8. Patients with an MPVLR ≥5.8 had a 3.141-fold increased risk of a poor outcome at 3 months (95% CI, 1.491–6.615; P = 0.003) compared to patients with an MPVLR <5.8. At 18–24 h after treatment with intravenous thrombolysis, the area under the curve of MPVLR to predict a poor outcome at 3 months was 0.697 (95% CI, 0.630–0.765, P < 0.001), and the best predictive MPVLR value was 6.9. The inclusion of MPVLR as a continuous (odds ratio, 1.145; 95% CI, 1.044–1.256, P = 0.004) and categorical variable (odds ratio, 6.555; 95% CI, 2.986–14.393, P < 0.001) was independently associated with poor outcomes at 3 months.Conclusions: Both the values of MPVLR at admission and 18–24 h after intravenous thrombolysis were independently associated with poor functional outcomes. MPVLR may serve as an activity marker for a poor prognosis in patients with acute ischemic stroke receiving intravenous thrombolysis.